Leerink Partnrs Reduces Earnings Estimates for CVS Health

CVS Health Co. (NYSE:CVS) – Analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for shares of CVS Health in a research report issued on Wednesday, December 18th. Leerink Partnrs analyst M. Cherny now anticipates that the pharmacy operator will post earnings per share of $0.98 for the quarter, down from their prior estimate of $1.24. The consensus estimate for CVS Health’s current full-year earnings is $5.32 per share. Leerink Partnrs also issued estimates for CVS Health’s Q2 2025 earnings at $1.66 EPS.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The business had revenue of $95.43 billion for the quarter, compared to analysts’ expectations of $92.72 billion. During the same quarter in the previous year, the business posted $2.21 earnings per share. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year.

A number of other research analysts have also recently commented on CVS. Mizuho lowered their target price on CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Evercore ISI increased their price target on shares of CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Piper Sandler dropped their price objective on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research note on Monday, November 25th. StockNews.com downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, UBS Group boosted their price target on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $69.12.

CVS Health Price Performance

Shares of NYSE CVS opened at $44.14 on Monday. CVS Health has a 1 year low of $43.56 and a 1 year high of $83.25. The stock has a market capitalization of $55.55 billion, a P/E ratio of 11.20, a P/E/G ratio of 0.85 and a beta of 0.54. The company’s 50-day moving average is $56.24 and its 200 day moving average is $58.21. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59.

Hedge Funds Weigh In On CVS Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. MidAtlantic Capital Management Inc. bought a new stake in CVS Health during the 3rd quarter worth approximately $25,000. Livelsberger Financial Advisory bought a new stake in shares of CVS Health during the 3rd quarter valued at $31,000. Legacy Investment Solutions LLC bought a new position in CVS Health in the 3rd quarter worth $31,000. Reston Wealth Management LLC purchased a new stake in CVS Health in the 3rd quarter worth $32,000. Finally, Kathleen S. Wright Associates Inc. bought a new stake in CVS Health during the third quarter valued at about $33,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.